

Advancing Glioblastoma Research and Care at Mass General



Fueling Progress for Our Patients

Every day, clinician-scientists from across Mass General deliver exceptional care, explore revolutionary technologies and develop therapeutic innovations with game-changing implications for patients with glioblastoma, the most common malignant brain tumor diagnosed in adults. We're making great progress — but we need to do more, and we need to do it faster.

Unfortunately, glioblastomas can be aggressive and may respond variably to different therapies. They tend to return even with therapy and thus require ongoing monitoring and treatment. There is an urgent need to develop more effective strategies and bring new hope to our patients and their families.

Mass General is leading the research and discovery needed to achieve a new standard of glioblastoma care. And philanthropy helps significantly accelerate our progress.

Since 2021, the **Jack Moran Memorial Golf Tournament** has raised **\$56,095** to change the way we understand and treat glioblastoma. Each gift made to benefit the Jack Moran Memorial Golf Tournament goes toward supporting important efforts that will have a meaningful impact on the patients and families we serve. With your support we will continue to transform therapies and deliver life-changing care.

Thank you for your partnership.



Our Future Directions

Your partnership helps us conduct groundbreaking research into new treatments and cures for glioblastoma, and develop state-of-the-art personalized therapies to take patient care to new levels. Funds support:

- **Personalized Cancer Medicine:** Our scientists study tumor cells in the laboratory to learn new information about their growth, develop models and form early ideas for treatments. When these ideas show promise in the lab, we bring them directly to the clinic through our clinical trials program, and provide early access to the most novel personalized cancer medicines. This well-developed scientific pathway has delivered many innovative treatments over the years, and with the current rate of discovery, possibilities continue to grow. There are many exciting opportunities on the horizon for personalized medicines — including targeted molecular therapies and immunotherapies — for glioblastoma, and we are working to bring these findings to patients as soon as possible.
- **Liquid Biopsy:** Drs. Stott and Nahed developed the first device to identify and capture brain tumor cell in the blood of patients — opening up a blood test to diagnose and monitor glioblastoma in patients. Expanding on this groundbreaking discovery, our team has developed a comprehensive blood test to capture circulating tumor cells (CTCs) and extra-cellular vesicles (EVs) which are shed by the tumor into the bloodstream. Developing a minimally invasive blood test will allow doctors to more accurately detect tumor recurrence and identify new molecular targets for next generation therapies — all with a goal to personalize the care of our brain tumor patients to specifically target their tumor while avoiding the risks of additional surgery.
- **Supportive Care:** Patients with glioblastoma experience significant distress associated with their illness and prognosis. The high burden of symptoms affecting the body and nervous system, coupled with the concern of future neurological decline, causes significant and understandable stress for patients and their families. Our team is leading innovative research to provide palliative and supportive care for patients with glioblastoma and their caregivers, and to improve communication between these patients, their caregivers and their clinicians.

Importance of Philanthropy

At this pivotal moment, our speed of philanthropic progress is crucial. Your support helps us accelerate progress by fueling the bold, innovative research most likely to produce true breakthroughs.

Your Gift Supports Our Brain Tumor Team



Deborah Forst, MD
Neuro-Oncologist
Mass General Cancer Center



Brian Nahed, MD, MSc
Neurosurgeon
Department of Neurosurgery



Shannon Stott, PhD
Engineer
Center for Cancer Research



To learn more about contributing to our efforts, please contact:

Sarah Gaylord, Senior Director of Development
sgaylord@mgh.harvard.edu • 617.797.5766
giving.massgeneral.org